Austin Hospital

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Retrieved on: 
Mercredi, avril 17, 2024
Software, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Health Technology, Technology, Mortality, Austin Hospital, Royal North Shore Hospital, Aminoglycoside, Hospital, Risk, Vancomycin, Safety, Research, Royal Perth Hospital, Attention, Acute kidney injury, HITRUST, Patient, Toxicity, AKI, Medicine, Algorithm, Pharmacist, Growth, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
  • The precision dosing software has informed over 400,000 dosing decisions, benefiting more than 10,000 patients and gaining the trust of over 1,000 clinicians nationwide.
  • “It is exciting to see the global demand around precision dosing, with Australia continuing to be a trailblazer,” said Paul Edwards, CEO of DoseMe.
  • This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe's commitment to global expansion and continuous innovation to deliver advanced precision dosing.

Ferronova - Nanoparticle Trial Begins in Patients With Gastric and Oesophageal Cancers

Retrieved on: 
Mardi, avril 9, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Neoplasm, Cancer, Abdomen, SAHMRI, Safety, Austin, Texas, Risk, Royal Adelaide Hospital, Oral cancer, Queen Elizabeth Hospital, Nanoparticle, Patient, RAH, Metastasis, MRI, Flinders Medical Centre, Lymph, Clinical trial, Associate, Austin Hospital, Medical imaging

Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in patients with gastric and oesophageal cancers.

Key Points: 
  • Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in patients with gastric and oesophageal cancers.
  • It follows the completion of a first-in-human trial in 2020-2022 in oral cancer patients.
  • Trial imaging is supported by the South Australian Health and Medical Research Institute (SAHMRI) and the National Imaging Facility.
  • They have all put in an incredible amount of work and planning to design and initiate this trial.